Pages that link to "Q38378907"
Jump to navigation
Jump to search
The following pages link to Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. (Q38378907):
Displaying 25 items.
- Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review (Q26770716) (← links)
- NK Cell Subgroups, Phenotype, and Functions After Autologous Stem Cell Transplantation (Q36310605) (← links)
- Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation (Q36794295) (← links)
- Success of an International Learning Health Care System in Hematopoietic Cell Transplantation: The American Society of Blood and Marrow Transplantation Clinical Case Forum (Q37136301) (← links)
- Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis (Q37388718) (← links)
- Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies (Q38612233) (← links)
- Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents. (Q38664909) (← links)
- PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher (Q38953155) (← links)
- Novel agents and strategies in transplant-eligible patients with relapsed and refractory Hodgkin lymphoma (Q39027789) (← links)
- PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. (Q40216708) (← links)
- Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: a SWOG and Blood & Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). (Q47229875) (← links)
- Autologous Stem Cell Transplantation After Second Line Brentuximab Vedotin in Relapsed or Refractory Hodgkin Lymphoma. (Q47562175) (← links)
- Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma (Q47563022) (← links)
- Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors (Q47855599) (← links)
- Pharmacotherapeutic Management of Pediatric Lymphoma. (Q48321203) (← links)
- Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma (Q48328423) (← links)
- Transplant strategies in relapsed/refractory Hodgkin lymphoma. (Q52676516) (← links)
- Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan. (Q52861703) (← links)
- Sequential immunotherapy in a patient with primary refractory Hodgkin lymphoma and novel mutations. (Q54213148) (← links)
- Etoposide phosphate hypersensitivity overcome using a desensitisation programme enabling optimal therapy for relapsed Hodgkin lymphoma. (Q54614312) (← links)
- Platelet Count before Peripheral Blood Stem Cell Mobilization Is Associated with the Need for Plerixafor But Not with the Collection Result. (Q55094338) (← links)
- Nivolumab for the Treatment of Classical Hodgkin Lymphoma. (Q55263099) (← links)
- Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT? (Q88321701) (← links)
- Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT (Q92402148) (← links)
- Allogeneic stem cell transplantation improves survival in relapsed Hodgkin lymphoma patients achieving complete remission after salvage treatment (Q92757994) (← links)